
A UK study involving 211,396 individuals with type 2 diabetes reveals that metformin therapy, the standard oral glucose-lowering treatment, is linked to a reduced risk of dementia and mild cognitive impairment (MCI) compared to other glucose-lowering therapies. Over a median follow-up of 5.4 years, metformin users exhibited a lower risk of dementia (14% reduction) and MCI (8% reduction). Notably, individuals under 80 years old experienced a more significant decrease in dementia risk. Researchers suggest a potential neuroprotective effect of metformin, emphasizing the need for further research to establish causality and address confounding factors.
Like
Save
Share